Lifecore Biomedical (LFCR) Competitors

Lifecore Biomedical (NASDAQ:LFCR) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Do insiders and institutionals hold more shares of LFCR or GPCR?

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 32.2% of Lifecore Biomedical shares are held by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, LFCR or GPCR?

Lifecore Biomedical has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$130.31M	2.27	$12.01M	-$1.45	-5.51
Structure Therapeutics	N/A	N/A	-$122.53M	-$0.87	-22.93

Do analysts rate LFCR or GPCR?

Lifecore Biomedical presently has a consensus price target of $8.00, suggesting a potential upside of 0.06%. Structure Therapeutics has a consensus price target of $76.17, suggesting a potential upside of 281.88%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Structure Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, LFCR or GPCR?

Lifecore Biomedical has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.87, suggesting that its stock price is 287% less volatile than the S&P 500.

Does the media prefer LFCR or GPCR?

In the previous week, Structure Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 2 mentions for Structure Therapeutics and 1 mentions for Lifecore Biomedical. Structure Therapeutics' average media sentiment score of 1.34 beat Lifecore Biomedical's score of 0.94 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lifecore Biomedical	Positive
Structure Therapeutics	Positive

Is LFCR or GPCR more profitable?

Structure Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -35.90%. Structure Therapeutics' return on equity of -16.35% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-35.90%	-551.09%	-13.89%
Structure Therapeutics	N/A	-16.35%	-15.71%

Summary

Structure Therapeutics beats Lifecore Biomedical on 9 of the 15 factors compared between the two stocks.